Xenon Pharmaceuticals (XENE) Total Non-Current Liabilities (2024 - 2026)

Xenon Pharmaceuticals (XENE) has 3 years of Total Non-Current Liabilities data on file, last reported at $45.7 million in Q1 2026.

• On a quarterly basis, Total Non-Current Liabilities changed N/A year-over-year to $45.7 million in Q1 2026; TTM through Mar 2026 was $45.7 million, a N/A change from a year earlier, with the FY2025 full-year figure at $48.2 million, up 11.49% from the prior year.
• Total Non-Current Liabilities for Q1 2026 stood at $45.7 million, down from $48.2 million in the prior quarter.
• Over the last five years, Total Non-Current Liabilities for XENE reached as high as $48.2 million in Q4 2025 and fell as low as $43.2 million in Q4 2024.
• Historically, Total Non-Current Liabilities has averaged $45.6 million across 3 years, with a median of $45.5 million in 2025.
• On a YoY basis, Total Non-Current Liabilities climbed as much as 11.49% in 2025 and fell as far as 11.49% in 2025.
• Year by year, Total Non-Current Liabilities stood at $43.2 million in 2024, then advanced by 11.49% to $48.2 million in 2025, then slipped by 5.1% to $45.7 million in 2026.
• Per Business Quant data, the three most recent Total Non-Current Liabilities figures were $45.7 million in Q1 2026, $48.2 million in Q4 2025, and $45.2 million in Q3 2025.